Case Vignettes in Metastatic Breast Cancer

Article

This case-based program is designed to educate healthcare providers on the optimal management of patients with ER+/HER2– MBC, with the goal of improving patient outcomes including quality of life and survival.

Activity Overview

This activity is designed to educate medical oncologists, surgical oncologists, radiation oncologists, oncology nurses, and other allied health professionals on the optimal management of metastatic breast cancer.

This case-based program is designed to educate these healthcare providers on the optimal management of patients with ER+/HER2— MBC, with the goal of improving patient outcomes including quality of life and survival.

To view this CME activity, click here >>>

Educational Objectives

Upon completing this activity as designed, participants should be able to:

  • Review clinical trial data on current and emerging treatments for patients with ER-positive/HER2-negative MBC
  • Evaluate efficacy and safety data on currently available chemotherapeutic agents for patients with ER-positive/HER2-negative MBC
  • Describe optimal management strategies recommended by evidence-based guidelines for the treatment of patients with ER-positive/HER2- negative MBC
  • Develop individualized treatment plans with consideration for key patient and clinical factors for patients with ER-positive/HER2-negative MBC

Target Audience:Medical oncologists, surgical oncologists, radiation oncologists, oncology nurses, and other allied health professionals.

Type of Activity:Knowledge

Release date:April 30, 2015

Expiration date:April 30, 2016

Estimated time to complete activity:2 hours

To view this CME activity, click here >>>

Featuring Consultations With

Joyce O'Shaughnessy, MD

Chair, Breast Cancer Research

Baylor-Sammons Cancer Center

Texas Oncology, US Oncology

Dallas, TX

Linda T. Vahdat, MD

Professor of Medicine

Director of the Breast Cancer Research Program,

Chief of the Solid Tumor Service

Weill Cornell Medical College

New York, NY

With Community Oncologist's Perspective by

Hussein Ali-Ahmad, MD

Clinical Assistant Professor of Oncology

Roswell Park Cancer Institute

Jamestown, NY

Editorial Support

Sigrid Eckhardt

Hitt Medical Writing, LLC

This activity is supported by an educational grant from Eisai.

To view this CME activity, click here >>>

Related Videos
Video 3 - "Adverse Event Profile and Tolerability of Fruquintinib Based on FRESCO-2 Trial"
Video 2 - "FRESCO-2 Study Design Overview"
Video 2 - "Overall Survival and Progression Free Survival in the FRESCO-2 Trial"
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Related Content